Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22577530 | 0.92 | HPGD (0.48) | HPGDADORA3ADORA2APDE2AADORA1 | |
| SCHEMBL20547890 | 0.87 | ADORA2A (0.55) | HPGDADORA3ADORA2APDE2AADORA1 | |
| SCHEMBL4858272 | 0.85 | HPGD (0.59) | HPGDADORA3ADORA2ALMNANT5E | |
| SCHEMBL20547587 | 0.79 | MEN1 (0.48) | HPGDADORA3ADORA2AADORA1LMNA | |
| SCHEMBL22577553 | 0.78 | HPGD (0.38) | HPGDADORA3ADORA2APDE2AADORA1 | |
| SCHEMBL20547914 | 0.76 | ADORA2A (0.38) | HPGDADORA3ADORA2APDE2AADORA1 | |
| SCHEMBL24258539 | 0.76 | SLC29A1 (0.42) | HPGDLMNANT5EPAX8SLC29A1 | |
| SCHEMBL4528206 | 0.74 | PNP (0.54) | PDE4DPDE3ALMNAHIF1ATP53 | |
| SCHEMBL21263936 | 0.72 | LMNA (0.48) | LMNANT5ETP53 | |
| SCHEMBL20908767 | 0.71 | ALDH1A1 (0.59) | HPGDPDE4DPDE3ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPGD 1650/4885ADORA3 117/4885ADORA2A 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.